Key result
A pharmacoinvasive strategy reduced 30-day shock and congestive heart failure compared with primary PCI in patients with small infarct size.
Why the study?
Does a pharmacoinvasive strategy alter infarct size and reduce 30-day shock and heart failure compared to primary PCI in early presenting STEMI patients?
RCT (n=1,701)
randomized
Does a pharmacoinvasive strategy alter infarct size and reduce 30-day shock and heart failure compared to primary PCI in early presenting STEMI patients?
A pharmacoinvasive strategy in early STEMI alters infarct size distribution and is associated with more aborted MIs and less 30-day shock or heart failure in patients with small infarcts compared to primary PCI.
Answers are grounded in this paper and cite their sources.
PI may reduce early shock and heart failure via more aborted infarcts; leaves open whether this extends to routine practice or larger trials.
BACKGROUND: A pharmacoinvasive (PI) strategy for early presenting ST-segment elevation myocardial infarction nominally reduced 30-day cardiogenic shock and congestive heart failure compared with primary percutaneous coronary intervention (PPCI). We evaluated whether infarct size (IS) was related to this finding. METHODS AND RESULTS: Using the peak cardiac biomarker in patients randomized to PI versus PPCI within the Strategic Reperfusion Early After Myocardial Infarction (STREAM) trial, IS was divided into 3 groups: small (≤2 times the upper limit normal [ULN]), medium (>2 to ≤5 times the upper limit normal) and large (>5 times the upper limit normal). The association between IS and 30-day shock and congestive heart failure was subsequently examined. Data on 1701 of 1892 (89.9%) patients randomized to PI (n=853, 50.1%) versus PPCI (n=848, 49.9%) within STREAM were evaluated. A higher proportion of PPCI patients had a large IS (PI versus PPCI: small, 49.8% versus 50.2%; medium, 56.9% versus 43.1%; large, 48.4% versus 51.6%; P=0.035), despite comparable intergroup ischemic times for each reperfusion strategy. As IS increased, a parallel increment in shock and congestive heart failure occurred in both treatment arms, except for the small IS group. The difference in shock and congestive heart failure in the small IS group (4.4% versus 11.6%, P=0.026) in favor of PI likely relates to higher rates of aborted myocardial infarction with the PI strategy (72.7% versus 54.3%, P=0.005). After adjustment, a trend favoring PI persisted in this subgroup (relative risk 0.40, 95% CI 0.15 to 1.06, P=0.064); no difference in treatment-related outcomes was evident in the other 2 groups. CONCLUSION: A PI strategy appears to alter the pattern of IS after ST-segment elevation myocardial infarction, resulting in more medium and fewer large infarcts compared with PPCI. Despite a comparable number of small infarcts, PI patients in this group had more aborted myocardial infarctions and less 30-day shock and congestive heart failure. CLINICAL TRIAL REGISTRATION: URL: http://ClinicalTrials.gov. Unique identifier: NCT00623623.
No takes yet. Share an insight, caveat, or question.
Shavadia et al. (2015) conducted an RCT in ST-segment elevation myocardial infarction (n=1,701). Pharmacoinvasive (PI) strategy vs. Primary percutaneous coronary intervention (PPCI) was evaluated on 30-day shock and congestive heart failure in the small infarct size subgroup (RR 0.40, 95% CI 0.15 to 1.06, p=0.064). A pharmacoinvasive strategy reduced 30-day shock and congestive heart failure compared with primary PCI in patients with small infarct size.
Synapse has enriched 10 related papers. Consider them for comparative context: